Maverix Names Carla Jung Chief Executive Officer to Lead Next Phase of Growth
Maverix Medical has appointed Carla Jung as Chief Executive Officer to lead its strategy and execution as the company seeks to expand its portfolio and patient impact in lung cancer care. Jung's leadership comes at a time when Maverix is scaling its commercial organization and developing new products.
Since acquiring Thoracent in early 2025, Maverix has significantly increased its customer base and commercial presence. The company was established to create a dedicated platform for lung cancer, which it is now expanding to enhance its clinical impact for patients and healthcare providers involved in lung cancer treatment.
Duke Rohlen, Founder and Chief Executive Officer of Ajax Health, praised Jung's ability to achieve results, stating that under her leadership as Chief Commercial Officer, the team has seen a revenue growth of more than 30 percent year over year. "Her dedication to her team and to giving physicians the best possible solutions for their patients is unmatched," he added.
As part of the leadership transition, David Beylik, who previously served as Chief Operating Officer, will move into the role of Executive Chair. Brian Lynch, recognized for building the Thoracent sales organization, has been appointed Chief Revenue Officer and President of the Medical Device Division.
With 29 years of experience in the medtech industry, Jung previously held the position of Vice President for Coronary and Renal Denervation at Medtronic, where she led the launch of over ten cardiovascular products during her 13-year tenure. She also spent eleven years in sales at Boston Scientific and started her career in women's health at Eli Lilly. Jung holds an MBA from Columbia University and a BA from Villanova University.
Jung expressed her honor in leading the team, emphasizing the importance of early diagnosis in lung cancer care. "Our ambition is to make an impact across the entire continuum of care, from detection through treatment, with the goal of helping more patients survive this disease," she stated.